MYC and neoplasm: In PARPi-insensitive BT74, there was no difference in survival between PARPi- and vehicle-treated groups (Fig. 1g, i), as we described previously18; however, MYC overexpression somewhat accelerated BT74 tumor growth (not significantly) and tumors now became responsive to olaparib (Fig. 1i).